コンテンツへスキップ
Merck

DrugBank 3.0: a comprehensive resource for 'omics' research on drugs.

Nucleic acids research (2010-11-10)
Craig Knox, Vivian Law, Timothy Jewison, Philip Liu, Son Ly, Alex Frolkis, Allison Pon, Kelly Banco, Christine Mak, Vanessa Neveu, Yannick Djoumbou, Roman Eisner, An Chi Guo, David S Wishart
要旨

DrugBank (http://www.drugbank.ca) is a richly annotated database of drug and drug target information. It contains extensive data on the nomenclature, ontology, chemistry, structure, function, action, pharmacology, pharmacokinetics, metabolism and pharmaceutical properties of both small molecule and large molecule (biotech) drugs. It also contains comprehensive information on the target diseases, proteins, genes and organisms on which these drugs act. First released in 2006, DrugBank has become widely used by pharmacists, medicinal chemists, pharmaceutical researchers, clinicians, educators and the general public. Since its last update in 2008, DrugBank has been greatly expanded through the addition of new drugs, new targets and the inclusion of more than 40 new data fields per drug entry (a 40% increase in data 'depth'). These data field additions include illustrated drug-action pathways, drug transporter data, drug metabolite data, pharmacogenomic data, adverse drug response data, ADMET data, pharmacokinetic data, computed property data and chemical classification data. DrugBank 3.0 also offers expanded database links, improved search tools for drug-drug and food-drug interaction, new resources for querying and viewing drug pathways and hundreds of new drug entries with detailed patent, pricing and manufacturer data. These additions have been complemented by enhancements to the quality and quantity of existing data, particularly with regard to drug target, drug description and drug action data. DrugBank 3.0 represents the result of 2 years of manual annotation work aimed at making the database much more useful for a wide range of 'omics' (i.e. pharmacogenomic, pharmacoproteomic, pharmacometabolomic and even pharmacoeconomic) applications.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リファンピシン, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
チメロサール, 97.0-101.0% (on dried substance, titration)
Sigma-Aldrich
トリメトプリム, ≥98.5%
Sigma-Aldrich
テトラサイクリン, 98.0-102.0% (HPLC)
Sigma-Aldrich
スペクチノマイシン 二塩酸塩 五水和物, potency: ≥603 μg per mg
Sigma-Aldrich
チアベンダゾール, ≥99%, powder
Sigma-Aldrich
トブラマイシン 硫酸塩, aminoglycoside antibiotic
Sigma-Aldrich
スペクチノマイシン, Ready Made Solution, 100 mg/mL in DMSO/H2O, 1:1
Sigma-Aldrich
テルビナフィン 塩酸塩
Sigma-Aldrich
ニトロフラントイン, 98.0-102.0% (EP, UV)
Sigma-Aldrich
ビンクリスチン 硫酸塩, 95.0-105.0% (HPLC), powder or crystals
Sigma-Aldrich
トブラマイシン, Aminoglycoside antibiotic
Sigma-Aldrich
スルファジアジン, 99.0-101.0%
Sigma-Aldrich
トリメトプリム 乳酸塩, ≥98%
Sigma-Aldrich
スルファメタジン, 99.0-101.0% (on dried basis)
Sigma-Aldrich
タゾバクタム ナトリウム塩, β-lactamase inhibitor
Sigma-Aldrich
ポリミキシンB 硫酸塩
Sigma-Aldrich
テイコプラニン
Sigma-Aldrich
Rifapentine
Sigma-Aldrich
リファキシミン
Sigma-Aldrich
チカルシリン 二ナトリウム塩
Sigma-Aldrich
スルファグアニジン
Sigma-Aldrich
Naftifine hydrochloride
Sigma-Aldrich
Penciclovir
Sigma-Aldrich
スルファメタジン ナトリウム塩, ≥98%
Sigma-Aldrich
チオ-TEPA
Sigma-Aldrich
スワインソニン, from Metarrhizium anisopliae, ≥98% (TLC)
Sigma-Aldrich
スルファメータ